Literature DB >> 30226456

Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.

Robert M Hicks1, Jeffry P Simko1, Antonio C Westphalen1, Hao G Nguyen1, Kirsten L Greene1, Li Zhang1, Peter R Carroll1, Thomas A Hope1.   

Abstract

Purpose To compare the diagnostic accuracy of gallium 68 (68Ga)-labeled prostate-specific membrane antigen (PSMA)-11 PET/MRI with that of multiparametric MRI in the detection of prostate cancer. Materials and Methods The authors performed a retrospective study of men with biopsy-proven prostate cancer who underwent simultaneous 68Ga-PSMA-11 PET/MRI before radical prostatectomy between December 2015 and June 2017. The reference standard was whole-mount pathologic examination. Readers were blinded to radiologic and pathologic findings. Tumor localization was based on 30 anatomic regions. Region-specific sensitivity and specificity were calculated for PET/MRI and multiparametric MRI by using raw stringent and alternative neighboring approaches. Maximum standardized uptake value (SUVmax) in the tumor and Prostate Imaging Reporting and Data System (PI-RADS) version 2 grade were compared with tumor Gleason score. Generalized estimating equations were used to estimate population-averaged sensitivity and specificity and to determine the association between tumor characteristics and SUVmax or PI-RADS score. Results Thirty-two men (median age, 68 years; interquartile range: 62-71 years) were imaged. The region-specific sensitivities of PET/MRI and multiparametric MRI were 74% (95% confidence interval [CI]: 70%, 77%) and 50% (95% CI: 45%, 0.54%), respectively, with the alternative neighboring approach (P < .001 for both) and 73% (95% CI: 68%, 79%) and 69% (95% CI: 62%, 75%), respectively, with the population-averaged generalized estimating equation (P = .04). Region-specific specificity of PET/MRI was similar to that of multiparametric MRI with the alternative neighboring approach (88% [95% CI: 85%, 91%] vs 90% [95% CI: 87%, 92%], P = .99) and in population-averaged estimates (70% [95% CI: 64%, 76%] vs 70% [95% CI: 64%, 75%], P = .99). SUVmax was associated with a Gleason score of 7 and higher (odds ratio: 1.71 [95% CI: 1.27, 2.31], P < .001). Conclusion The sensitivity of gallium 68-labeled prostate-specific membrane antigen-11 PET/MRI in the detection of prostate cancer is better than that of multiparametric MRI. © RSNA, 2018 See also the editorial by Civelek in this issue.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226456      PMCID: PMC6283324          DOI: 10.1148/radiol.2018180788

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

Authors:  Felix K-H Chun; Thomas Steuber; Andreas Erbersdobler; Eike Currlin; Jochen Walz; Thorsten Schlomm; Alexander Haese; Hans Heinzer; Michael McCormack; Hartwig Huland; Markus Graefen; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2005-12-22       Impact factor: 20.096

2.  68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters.

Authors:  Stefan A Koerber; Maximilian T Utzinger; Clemens Kratochwil; Claudia Kesch; Matthias F Haefner; Sonja Katayama; Walter Mier; Andrei H Iagaru; Klaus Herfarth; Uwe Haberkorn; Juergen Debus; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-15       Impact factor: 10.057

3.  Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator.

Authors:  Raviteja Nanabala; Muhammed K Anees; Arun Sasikumar; Ajith Joy; M R A Pillai
Journal:  Nucl Med Biol       Date:  2016-05-13       Impact factor: 2.408

4.  Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.

Authors:  Thomas A Hope; Rahul Aggarwal; Bryant Chee; Dora Tao; Kirsten L Greene; Matthew R Cooperberg; Felix Feng; Albert Chang; Charles J Ryan; Eric J Small; Peter R Carroll
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

5.  Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging.

Authors:  Berrend G Muller; Joanna H Shih; Sandeep Sankineni; Jamie Marko; Soroush Rais-Bahrami; Arvin Koruthu George; Jean J M C H de la Rosette; Maria J Merino; Bradford J Wood; Peter Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2015-06-18       Impact factor: 11.105

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Expression of the prostate-specific membrane antigen.

Authors:  R S Israeli; C T Powell; J G Corr; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.

Authors:  Jeffrey S Ross; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Iain Webb; Gary S Gray; Rebecca Mosher; Bhaskar V S Kallakury
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

9.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

Authors:  C Marchal; M Redondo; M Padilla; J Caballero; I Rodrigo; J García; J Quian; D G Boswick
Journal:  Histol Histopathol       Date:  2004-07       Impact factor: 2.303

10.  Imaging for Prostate Cancer Recurrence.

Authors:  Tobias Maurer; Matthias Eiber; Stefano Fanti; Lars Budäus; Valeria Panebianco
Journal:  Eur Urol Focus       Date:  2016-02-22
View more
  41 in total

Review 1.  Multimodality Imaging of Prostate Cancer.

Authors:  Soleen Ghafoor; Irene A Burger; Alberto H Vargas
Journal:  J Nucl Med       Date:  2019-09-03       Impact factor: 10.057

2.  Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.

Authors:  Jie Gao; Chengwei Zhang; Qing Zhang; Yao Fu; Xiaozhi Zhao; Mengxia Chen; Bing Zhang; Danyan Li; Jiong Shi; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-25       Impact factor: 9.236

3.  Combination of 68Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

Authors:  Mengxia Chen; Qing Zhang; Chengwei Zhang; Xiaozhi Zhao; Giancarlo Marra; Jie Gao; Xiaoyu Lv; Bing Zhang; Yao Fu; Feng Wang; Xuefeng Qiu; Hongqian Guo
Journal:  J Nucl Med       Date:  2018-12-14       Impact factor: 10.057

4.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

5.  Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI.

Authors:  Francesco Paparo; Alice Peirano; João Matos; Lorenzo Bacigalupo; Umberto Rossi; Ilaria Mussetto; Gianluca Bottoni; Martina Ugolini; Carlo Introini; Filippo Grillo Ruggieri; Gian Andrea Rollandi; Arnoldo Piccardo
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 6.  [Hybrid imaging in prostate cancer : Status quo and future applications].

Authors:  Michal-Kamil Chodyla; Matthias Eiber; Axel Wetter; Isabel Rauscher
Journal:  Radiologe       Date:  2020-05       Impact factor: 0.635

Review 7.  Recent Advances in Cancer Imaging with 64CuCl2 PET/CT.

Authors:  Fangyu Peng
Journal:  Nucl Med Mol Imaging       Date:  2022-02-17

8.  Efficacy of 68Ga-PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study.

Authors:  Yi Nuo; Aimei Li; Lulu Yang; Hailin Xue; Feng Wang; Liwei Wang
Journal:  Quant Imaging Med Surg       Date:  2022-01

Review 9.  New imaging modalities to consider for men with prostate cancer on active surveillance.

Authors:  Yasin Bhanji; Steven P Rowe; Christian P Pavlovich
Journal:  World J Urol       Date:  2021-06-19       Impact factor: 4.226

Review 10.  Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers.

Authors:  Zhaoguo Han; Mingxing Ke; Xiang Liu; Jing Wang; Zhengqi Guan; Lina Qiao; Zhexi Wu; Yingying Sun; Xilin Sun
Journal:  Mol Imaging Biol       Date:  2021-07-16       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.